Financhill
Sell
37

KRMD Quote, Financials, Valuation and Earnings

Last price:
$3.99
Seasonality move :
28.58%
Day range:
$3.61 - $4.03
52-week range:
$1.98 - $4.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.75x
P/B ratio:
10.39x
Volume:
209.2K
Avg. volume:
75.7K
1-year change:
74.03%
Market cap:
$184.3M
Revenue:
$28.5M
EPS (TTM):
-$0.25

Analysts' Opinion

  • Consensus Rating
    KORU Medical Systems has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of --, KORU Medical Systems has an estimated upside of 21.89% from its current price of $4.02.
  • Price Target Downside
    According to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $4.02.

Fair Value

  • According to the consensus of 0 analysts, KORU Medical Systems has 21.89% upside to fair value with a price target of -- per share.

KRMD vs. S&P 500

  • Over the past 5 trading days, KORU Medical Systems has underperformed the S&P 500 by -4.62% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • KORU Medical Systems does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • KORU Medical Systems has grown year-over-year revenues for 3 quarters straight. In the most recent quarter KORU Medical Systems reported revenues of $8.2M.

Earnings Growth

  • KORU Medical Systems earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter KORU Medical Systems reported earnings per share of -$0.03.
Enterprise value:
175.9M
EV / Invested capital:
9.70x
Price / LTM sales:
5.75x
EV / EBIT:
--
EV / Revenue:
5.50x
PEG ratio (5yr expected):
-0.34x
EV / Free cash flow:
-100.22x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$20.1M
Return On Assets:
-41%
Net Income Margin (TTM):
-37.42%
Return On Equity:
-57.92%
Return On Invested Capital:
-57.18%
Operating Margin:
-20.82%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $27M $28.7M $32M $7M $8.2M
Gross Profit $15.1M $16.5M $20.1M $4.3M $5.2M
Operating Income -$10.4M -$10.6M -$7.1M -$1.8M -$1.7M
EBITDA -$9.9M -$9.8M -$6.1M -$1.6M -$1.5M
Diluted EPS -$0.18 -$0.17 -$0.25 -$0.03 -$0.03
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $42.6M $37.7M $30.7M $21.7M $18.9M
Total Assets $45.4M $41.4M $42.7M $35.4M $27.4M
Current Liabilities $5.4M $4.6M $6.2M $4.2M $6.3M
Total Liabilities $5.5M $4.6M $10.2M $7.9M $9.7M
Total Equity $39.9M $36.8M $32.5M $27.4M $17.7M
Total Debt -- $673.1K $644.7K $466K $402K
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$7.5M -$4.7M -$162.5K -$1.2M -$924K
Cash From Investing -$2.6M -$830.1K -$1.6M -$213.7K -$1.1M
Cash From Financing $291.4K -$186.1K -$211.2K $441.3K $374.5K
Free Cash Flow -$10.1M -$5.5M -$1.8M -$1.4M -$2M
KRMD
Sector
Market Cap
$184.3M
$43.9M
Price % of 52-Week High
87.39%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
74.03%
-29.11%
Beta (5-Year)
0.476
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $4.04
200-day SMA
Buy
Level $2.59
Bollinger Bands (100)
Buy
Level 2.27 - 3.47
Chaikin Money Flow
Buy
Level 17.3M
20-day SMA
Buy
Level $3.93
Relative Strength Index (RSI14)
Buy
Level 56.95
ADX Line
Buy
Level 12.26
Williams %R
Neutral
Level -54.2056
50-day SMA
Buy
Level $3.27
MACD (12, 26)
Buy
Level 0.19
25-day Aroon Oscillator
Buy
Level 76
On Balance Volume
Neutral
Level 701.8K

Financial Scores

Buy
Altman Z-Score (Annual)
Level (7.6284)
Sell
CA Score (Annual)
Level (-0.4008)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (2.7842)
Buy
Piotroski F Score (Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (5)

Revenue Forecast

Earnings per Share Forecast

Company Profile

KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets, and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Stock Forecast FAQ

In the current month, KRMD has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The KRMD average analyst price target in the past 3 months is --.

  • Where Will KORU Medical Systems Stock Be In 1 Year?

    According to analysts, the consensus estimate is that KORU Medical Systems share price will rise to -- per share over the next 12 months.

  • What Do Analysts Say About KORU Medical Systems?

    Analysts are divided on their view about KORU Medical Systems share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that KORU Medical Systems is a Sell and believe this share price will drop from its current level to --.

  • What Is KORU Medical Systems's Price Target?

    The price target for KORU Medical Systems over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is KRMD A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for KORU Medical Systems is a Buy. 0 of 0 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of KRMD?

    You can purchase shares of KORU Medical Systems via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase KORU Medical Systems shares.

  • What Is The KORU Medical Systems Share Price Today?

    KORU Medical Systems was last trading at $3.99 per share. This represents the most recent stock quote for KORU Medical Systems. Yesterday, KORU Medical Systems closed at $4.02 per share.

  • How To Buy KORU Medical Systems Stock Online?

    In order to purchase KORU Medical Systems stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

If you want to invest in an AI-leading tech company,…

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is up 4.46% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 10.25% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 4.77% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock